DUBLIN – Advicenne SA plans to seek European approval in the second half of next year for ADV-7103 for treating distal renal tubular acidosis on the back of data from an open-label phase III trial, in which the drug attained its primary endpoint, demonstrating its noninferiority vs. the standard of care.